Propofol and ketamine

Phase 1Small molecule

ZZagazig University

Propofol and ketamine is one of 3 small molecule programs targeting Sedation. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Enhanced RecoveryEnrolling by invitation

Enhanced RecoveryPhase 1

Enrolling by invitation

Competition

Competitive Landscape

4 competitors in Enhanced Recovery

#DrugCompanyPhaseTrials

Duragesic

CCephalon

Phase 1

1 2

Propofol and ketamine

ZZagazig University

Phase 1

1 3

Tramadol Plus Paracetamol

ZZagazig University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sedation1 trial

Oropharyngeoesophageal Topical Anesthesia Versus Propofol - Ketamine Sedation for Upper Gastrointestinal Endoscopy

Completed·ZZagazig University·N/A·NCT06566326·60 enrolled

Enhanced Recovery1 trial

Paracetamol Plus Tramadol Versus Fentanyl As Preemptive Analgesia For Enhanced Recovery After Day Case Surgeries

Enrolling by invitation·ZZagazig University·Phase 1·NCT06561672·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Propofol and ketamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Propofol and ketamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Propofol and ketamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zagazig University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: ZZagazig University

Propofol and ketamine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sedation1 trial

Enhanced Recovery1 trial

References

Drug Info

Quick Facts

Related News